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Brain metastasis, the secondary growth of malignant cells within the central nervous 
system (CNS), exceeds the incidence of primary brain tumors (i.e., gliomas) by tenfold 
and are seemingly on the rise owing to the emergence of novel targeted therapies that 
are more effective in controlling extracranial disease relatively to intracranial lesions. 
Despite the fact that metastasis to the brain poses a unmet clinical problem, with afflicted 
patients carrying significant morbidity and a fatal prognosis, our knowledge as to how 
metastatic cells manage to adapt to the tissue environment of the CNS remains limited. 
Answering this question could pave the way for novel and more specific therapeutic 
modalities in brain metastasis by targeting the specific makeup of the brain metastatic 
niche. In regard to this, astrocytes have emerged as the major host cell type that cancer 
cells encounter and interact with during brain metastasis formation. Similarly to other 
CNS disorders, astrocytes become reactive and respond to the presence of cancer cells 
by changing their phenotype and significantly influencing the outcome of disseminated 
cancer cells within the CNS. Here, we summarize the current knowledge on the contri-
bution of reactive astrocytes in brain metastasis by focusing on the signaling pathways 
and types of interactions that play a crucial part in the communication with cancer cells 
and how these could be translated into innovative therapies.
Keywords: brain metastasis, reactive astrocytes, metastases therapy, microenvironment heterogeneity, astrocyte 
signaling
iNTRODUCTiON
Brain metastasis defines the secondary tumor formation within the brain and typically results from 
metastases of lung cancer, breast cancer and melanoma together with other primary tumors that 
less frequently metastasize in the brain, such as colorectal cancer (1). We will focus on metastatic 
cells invading the brain parenchyma in contrast to the less frequent invasion of the leptomeninges 
by cancer cells, which has a very different biology derived from its location (meningeal space filled 
with cerebrospinal fluid) and cellular components of the microenvironment (2). Brain metastasis 
accounts for the major part of intracranial malignancies (3) and its incidence has been suggested 
to be on the rise owing to: improved imaging modalities as well as a generally lower threshold to 
schedule MRI imaging by physicians nowadays, extension of overall survival time of patients being 
treated with targeted antibody-based therapies (e.g., trastuzumab) or small molecule inhibitors 
(e.g., the small molecule ALK kinase inhibitor crizotinib), thus increasing likelihood for recur-
rence with central nervous system (CNS) lesions accounting for a main part of relapses, “sanctu-
ary site levels” of pharmacological agents because of poor drug penetration as demonstrated for 
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trastuzumab (4–7). Upon diagnosis of brain metastasis, affected 
patients suffer from significantly increased overall morbidity and 
mortality (1). Aside from being recognized as a serious obstacle 
to the care of cancer patients, only recently new insights into 
the molecular mechanisms accounting for metastatic spread to 
and growth within the brain have been made and new trials for 
assessing treatments in brain metastasis have been initiated to 
avoid traditional exclusion of this patient collective (8). Over 
the past decade, metastasis research with regard to the use of 
experimental mouse models of brain metastasis shed some light 
into the molecular and cellular events inherent to cancer cell 
dissemination and growth in the brain, which likely depends on 
the evolution of a series of cancer cell traits that are not neces-
sarily required and exploited in other extracranial locations and 
that continue to be characterized (9–18). Though metastatic 
organotropism (site-specific metastasis) to different organs 
seems to employ some shared molecular mechanisms involved in 
cancer cell–host cell interactions across different tumor entities, 
metastasis to the brain as such is unprecedented in that the brain 
microenvironment harbors unique cellular and non-cellular 
elements and a higher degree of isolation and protection medi-
ated by the blood–brain barrier (BBB) from both circulating 
molecules and cells found in the systemic circulation. Therefore, 
it is conceivable that cancer cells that are able to trespass the BBB 
and extravasate from brain capillaries face a complete different 
and unfamiliar tissue microenvironment subjecting cancer cells 
to strong selective forces (10, 19). Accordingly, cancer cells 
that are able to generate macrometastasis correspond to those 
seeds with the highest ability to integrate in such a demanding 
microenvironment, arguing against the BBB as the solely impedi-
ment to colonize and initiate outgrowth in the brain. The brain 
includes not only neurons but also glia. The glial compartment 
is involved in responding to any type of brain injury, such as 
astrocytes and microglia, the two main glial cell types together 
with oligodendrocytes, have been reported surround brain 
metastases (10, 20). Although the role of oligodendrocytes and, 
to a less extent, microglia has been poorly studied (21–23) in 
the context of brain metastasis, relatively abundant bibliography 
have considered brain metastasis-associated astrocytes. In this 
regard, recent discoveries provide compelling evidence that 
astrocytes, the major glial cell in the CNS, play an intricate role in 
brain metastasis by engaging different modes of interactions with 
incoming cancer cells. Although our knowledge on the crosstalk 
between astrocytes and cancer cells is still insufficient, recent 
seminal findings indicate that interactions with astrocytes occur 
at both early and late stages of the colonization process. Given 
that these interactions could provide both anti- and prometa-
static stimuli to cancer cells characterizing them might aid in dis-
secting the molecular machinery in order to explore innovative 
targeted therapeutics in brain metastasis. Here, we summarize 
them to expose the importance of astrocytes in the biology of 
brain metastasis. We envision that understanding the impact of 
astrocytes, as one of the key host cell type in the pathogenesis 
of brain metastasis, may serve not only to understand the func-
tional importance of the microenvironment in the development 
of this secondary tumor growth in the brain, but also to explore 
additional implications related to biomarkers and therapies.
wHAT ARe ReACTive ASTROCYTeS 
(RAs) AND HOw HAve THeY BeeN 
STUDieD?
Reactive astrocytes are ubiquitously present in any brain injury 
(24, 25). As such they have been extensively described surround-
ing brain tumors including brain metastasis (10, 12, 20, 26, 27). 
Usually they are identified by their profound alterations including 
the gain of a hypertrophic phenotype as well as the upregulation 
of the cytoskeletal intermediate filament protein glial fibrillary 
acidic protein (GFAP) (24, 25). However, the word reactive indi-
cates a more extensive number of changes (24) to be able to face 
a situation in which homeostasis has been compromised. There 
are many stimuli that could be informative to astrocytes of such a 
situation and which are commonly classified as danger-associated 
molecular patterns (DAMPs) and pathogen-associated molecular 
patterns (PAMPs) (28). PAMPs are generated by microbial infec-
tions (e.g., LPS) and usually provoke a primary immune response 
in the CNS through microglial cells and perivascular macrophages. 
In contrast, the exact identity and origin of DAMPs responsible to 
activate the reactive program in astrocytes in the context of brain 
metastasis remains unknown. The fact that very limited number 
of cancer cells, independently of the source of the primary tumor 
or oncogenomic profiles, from very early stages of colonization 
(i.e., when lodged with the brain capillaries during the process 
of extravasation) (10, 20) are able to trigger this response might 
indicate that, at least at these initial phases, tissue injury induced 
by cancer cells rather than DAMPs produced by cancer cells, 
would be responsible for triggering the activation. Throughout 
cancer cell evolvement and proliferation in the CNS the stimuli 
influencing the reactive state in astrocytes might underlie changes. In 
this sense different phases related to the behavior of RAs toward 
insults or tissue injuries have been described encompassing an 
acute phase and a chronic one, which is usually referred as to glial 
scar (24). The acute phase is usually responsible for limiting the 
extension of the damage (29), however, if this cannot be achieved 
the response becomes chronic, which usually impairs the ability 
of the CNS tissue to recover from the damage completely (30, 31). 
Additionally, different types of brain injuries have been associated 
with different transcriptomic changes in RAs (32, 33), which has 
lead to the proposal of a dichotomy similar to the one initially 
applied to macrophages and microglia (34). A similar situation 
seems to take place in the context of brain metastasis. Early on, 
RAs acting as a primary host defense efficiently limit the progres-
sion of incoming metastatic cells (10), whereas later RAs have 
been extensively described to promote the growth of cancer cells 
(9, 35–38).
A significant proportion of publications considering RAs in 
the field of brain metastasis research are based on data generated 
in vitro exclusively, using primary mouse astrocytes or an immor-
talized astrocyte cell line (27, 39–43). Techniques for in  vitro 
culture of astrocytes were described long time ago (44), however, 
recent data have demonstrated important considerations that 
must be taken into account. Most common protocols use early 
postnatal brains to obtain primary cultures of astrocytes (44). 
Since young and aged astrocytes could differ molecularly (45, 46) 
these astrocytes might not mimic those coexisting with cancer 
TABle 1 | Research goals for brain metastasis-associated reactive astrocytes.
1 Incorporate novel approaches to manipulate astrocytes in vitro (i.e., 
immunopanning) and in vivo (i.e., GEMM).
2 Apply unbiased genomic and proteomic analysis of reactive astrocytes (single 
cell level and population level) associated with brain metastasis from different 
primary sources (i.e., lung cancer, breast cancer, melanoma).
3 Comparison of brain metastasis-associated reactive astrocytes with those 
present in other brain injuries (i.e., primary brain tumors, neurodegenerative 
disorders, ischemia, traumatic brain injury, autoimmune disorders).
4 Identify and characterize specific subpopulations within brain metastasis-
associated reactive astrocytes and evaluate their potential therapeutic 
implications.
5 Dissect the biology behind antimetastatic and prometastatic reactive 
astrocytes: Are they different subpopulations? Do they coexist in time? 
Could prometastatic reactive astrocytes be transformed into antimetastatic 
astrocytes?
6 Does systemic disease (primary tumor and extracranial metastases) influence 
the brain microenvironment acting on reactive astrocytes before metastases 
are established in the brain?
7 Do brain metastasis-associated reactive astrocytes influence systemic 
disease outside the brain and/or organismal homeostasis as shown in other 
brain disorders?
8 Could reactive astrocytes associated with brain metastasis be the source of 
biomarkers for early diagnosis or response to therapy?
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cells in the brain. Another caveat of working with astrocytes 
in  vitro is that under regular culture conditions they instantly 
become reactive. In fact, the most widely applied method to 
assure the purity of the culture is to evaluate that >90% of the cells 
are GFAP+ (47). Since inducers of the reactive state in vitro likely 
differ from those present in secondary brain tumors, in  vitro 
asytrocyte cultures used in these studies unlikely reproduce the 
disparity of phenotypes associated with RAs in vivo (48). Thus, 
validation of in vitro findings using in vivo approaches is an abso-
lute requirement (a sine qua non condition) to generate reliable 
data aimed to develop potential therapeutics to target astrocytes 
in disease.
More advanced cultures including the addition of other cell 
types from the brain (10, 33), ex vivo brain organotypic cultures 
(10, 49) or brain organoids (50) are excellent platforms since 
they recapitulate closer the in vivo situation. Importantly, when 
applying these more sophisticated in  vitro approaches it was 
found that the antimetastatic behavior of RAs, occurring during 
the early stages of colonization in vivo, was reproduced (10, 49). 
Alternatively, novel methodologies based on immunopanning 
allow avoiding the default reactive state of this cell type in cul-
ture (45). Interspecies variability and cross-species differences 
in cell–cell interactions need to be considered when working 
with non-syngeneic in vitro or in vivo systems. Differences have 
been reported between murine and human astrocytes regarding 
different aspects of their biology including the complexity of 
arborization, calcium response properties and transcriptomic 
profiles (47). Consequently findings obtained with mouse 
astrocytes, require validation in human samples if knowledge 
generated is aimed to be translated in a bench-to-bedside 
manner.
Up to now, studies involving RAs in situ are based on fixed tis-
sue samples that evaluate GFAP+ cells (9, 10, 20, 37, 51) and none 
of them have reported the use of engineered astrocytes in vivo in 
the context of brain metastasis. However, as the interest in brain 
metastasis-associated RAs is gaining momentum and their exami-
nation will presumably be expanded toward the use of available 
and widely validated tools such as genetically engineered mouse 
models (GEMMs) that could drive reporters and/or genes of 
interest (29, 52, 53) in astrocytes or alternative approaches such as 
adeno-associated virus that target astrocytes (54) as well as in vivo 
electroporation with Star Track technology (55). Such experi-
mental resources will need to be combined with brain metastasis 
models in order to determine the impact of the modifications 
introduced in astrocytes in the process of brain colonization by 
cancer cells. Spontaneous brain metastases from orthotopic injec-
tions of cancer cells (injection in the organ source of the primary 
tumor from which brain metastasis models were established) or 
GEMM that develop primary tumors are rare events and difficult 
to study (18, 56, 57). In contrast, models in which brain metastases 
are induced upon inoculation of metastatic cells in the circulation 
(9–12, 58–61) are compatible to study the interaction between 
metastatic cells and RAs during brain colonization. In these 
models functional experiments to dissect these interactions can 
be performed and analyzed using a variety of techniques such as 
non-invasive molecular imaging, intravital imaging and detailed 
histology. Whether reported differences between mice and human 
astrocytes (47) are relevant in the context of brain metastasis will 
require specific validation of experimental findings in human 
samples. Given the broad diversity of brain metastasis models 
including different tumor types, oncogenomic profiles and differ-
ent species of cancer cells (human and mouse), the use of several 
available experimental models to confirm potential mediators of 
the interaction between cancer cells and astrocytes will be a good 
strategy to reach relevant conclusions with higher possibilities to 
be translated to patients (Table 1).
Thus, a growing number of resources to study RAs will 
certainly help to understand the complexity underlying their 
reciprocity with cancer cells in brain metastasis.
ASTROCYTeS AS A SOURCe  
OF SeCReTeD MOleCUleS
Main findings related to reactive astrocytes in the context of brain 
metastasis usually include the secretory nature of this glial cell 
type (Table  2). Upon the first encounter with metastatic cells 
RAs produce plasminogen activators (PAs), including secreted 
tissue PA. PAs have the ability to transform plasminogen into the 
protease plasmin which is responsible for the elimination of many 
cancer cells that cross the BBB (10). Consequently, the secretory 
ability of RAs during the initial stages of colonization limit meta-
static progression (Figure 1). However, few cancer cells produce 
anti-PA serpins and consequently block the antitumor program 
derived from RAs (10). Cancer cells with the ability to counteract 
the innate defense of RAs will continue colonizing the brain. 
Conversely, upon the development and growth of metastasis, RAs 
have been shown to generate a protumorigenic niche through 
various mechanisms involving secreted molecules. For instance, 
increased expression of COX2 in brain metastatic cancer cells 
FigURe 1 | Crosstalk between cancer cells and reactive astrocytes in brain 
metastasis. Cancer cells (in green) and astrocytes (in gray) are depicted with 
several of the molecular mechanisms described in their reciprocal crosstalk. 
The initial ability of reactive astrocytes to kill cancer cells through the 
production of Plasminogen activators is later modified into a supportive niche 
that involves secreted molecules, gap junctions, protocadherins, Notch 
receptor and ligands, among other components. Such a complex 
interactome influences each other cell type at the gene expression level.
TABle 2 | Secreted molecules by brain metastasis-associated reactive astrocytes.
RA secreted molecules Phenotype in cancer cells Cancer type Reference
ET-1 Induction of cancer cell growth and stemness through activation of MAPK and AKT Breast and lung cancer Kim et al. (35)
IL-23 Increase invassiveness by inducing MMP2 Melanoma Klein et al. (65)
HGF/SCF Induction of proangiogenic cytokines by activating c-Met Breast cancer Xing et al. (63).
BDNF Induction of cancer cell growth through activation of TrKB-HER2 Breast cancer Choy et al. (36)
CCL7 Induction of tumor initiating potential in cancer cells Breast cancer Wu et al. (62)
MMP2/MMP9 Increase invassiveness of cancer cells Breast cancer Wang et al. (67)
miR-19a Induction of cancer cell growth by targeting PTEN Breast cancer and melanoma Zhang et al. (37)
Hyaluronic acid Induction of cancer cell growth and stemness through activation of MAPK and AKT Lung cancer Stevens et al. (38)
IFNα/TNFα Induction of cancer cell growth and chemoresistance by STAT1 and NFκB Breast and lung cancer Chen et al. (9)
PA-Plasmin-FasL Decrease the viability of non-brain-adapted cancer cells Breast and lung cancer Valiente et al. (10)
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(MDA231BrM) has been linked to astrocyte activation and the 
production of CCL7 by this glial cell type (62). Astrocyte-derived 
CCL7 was associated with an increase in CD24low-CD44high-
ESAhigh subpopulation of MDA231BrM cells. Additional 
paracrine cytokine signaling loops between tumor-associated 
astrocytes and cancer cells in breast cancer brain metastasis have 
been described (Table 2). Astrocytes secrete hepatocyte growth 
factor/scatter factor (HGF/SF) under the influence of cancer 
cell-derived IL1β (Figure 1). Targeting this mutual c-Met-HGF 
crosstalk between cancer cells and tumor-associated astrocytes by 
using the BBB-permeable compound Pterostilbene, a resveratrol 
analog, diminished the stem-like cell phenotype dependent upon 
this feed-forward signaling loop both in vitro and in vivo (63). 
Another growth factor, namely BDNF, was suggested to be linked 
to the interplay between astrocytes and breast cancer cells in brain 
metastasis. Astrocyte-derived BDNF can favor cancer cell prolif-
eration by engaging heterodimerization of both Her2/NEU and 
TrkB receptors in vitro. Importantly, inhibition of this crosstalk 
by means of knocking down TrkB in cancer cells abrogated brain 
metastasis in vivo (36). In line with these studies, a previous one 
reported that brain metastatic cancer cells significantly up regu-
late IL-1β, which again seems to be embedded in a mutual signal-
ing loop between cancer cells and astrocytes. This was associated 
with a cancer cell-mediated activation of astrocytes, reflected by 
a heightened expression and production of astrocytic Jagged1 
in a NFκβ-dependent manner (64) (Figure 1). Accordingly, the 
resulting paracrine interaction between Jagged1  +  astrocytes 
and cancer cells was able to increase the stem-like phenotype in 
cancer cells via the Notch-Hes5 pathway (64). In the context of 
melanoma-to-brain metastasis evidences exist arguing about the 
ability of cancer cells to reprogramme astrocytes (understood as 
the induction of transcriptional modifications providing promet-
astatic functions). Cancer cells were able to induce the production 
of IL-23 in RAs. This proinflammatory cytokine was shown to be 
of importance in the up-regulation of cancer cell-derived MMP2, 
which in turn mediates invasiveness of brain metastatic mela-
noma cells in vitro. Blocking this paracrine interaction either by 
pharmacological inhibition of IL-23 or by knocking down cancer 
cell MMP2 resulted in inhibition of melanoma invasion in vitro 
(65). A recent study further supports a potential role of MMP2 
in breast-to-brain metastasis, as it was found to belong to 5-gene 
expression signature (together with CXCL12, MMP11, VCAM1, 
MME) discriminating between primary breast cancer and breast 
cancer brain metastases (66). To sum up, it seems to be evident 
that cancer cells get assistance originating from astrocytes after 
hijacking those and/or transforming them into passive bystand-
ers sustaining migration and growth as well as tumor-initiating 
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FigURe 2 | Pathway analysis on the influence of astrocytes on cancer cells in vitro. Bioinformatic analysis of available datasets reporting transcriptome of cancer 
cells upon coculture with astrocytes (27, 68) allowed us to obtain commonly 264 upregulated and 500 downregulated pathways. Some of these pathways are 
shown. Reg, regulation; Extr, extrinsic; Intr, intrinsic; Sign, signaling; Path, pathway.
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CANCeR Cell–ASTROCYTe 
iNTeRACTiONS THROUgH gAP 
JUNCTiONS
Astrocytes form an interconnected network that allows signal 
transduction in a coordinated manner (69). Key players in this 
communication are gap junctions. Gap junctions are composed of 
connexins (Cxs). Out of the 21 reported Cxs, Cx43 (also referred 
to as GJA1) and Cx30 (GJB6) are the most abundant in the adult 
brain (69). In physiology, astrocytic gap junctions are required 
for proper neuronal activity, synaptic transmission, energy 
supply and control of blood flow (69). When astrocytes become 
reactive their functional and spatial domains can be altered 
which might also modify their connectivity (70). Interestingly, 
initially in  vitro (27, 40) and later in  vivo (9), brain metastatic 
cells have been shown to be able to establish gap junctions with 
RAs. Why do brain metastatic cells have developed this ability? 
The Fidler lab addressed whether besides secreted molecules 
from RAs additional interactions involving physical contact 
with cancer cells could benefit them (27, 40). Their rationale was 
based on the conspicuous proximity between some cancer cells 
from established metastasis and RAs in  vivo (41). Their series 
of articles probed the physical interaction between them, its 
dependency on Cxs and the benefit it provided to cancer cells 
(27, 40). Through this cell–cell interaction, astrocytes induced the 
expression of 205 genes in different cancer cell lines from breast 
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and lung cancer (27). Although this gene program was expected 
to be Cx-dependent, the authors did not clarify this aspect since 
replicas including carbenoxolone, a gap junction inhibitor, or 
shRNA against Cx43 were not part of the transcriptomic profile. 
Hence, the resulting assumptions drawn from this gene list war-
rant further evaluation in respect to the dependency on Cx43. 
This concern was further enlarged given their findings by which 
calcein (a gap junction permeable molecular dye) is also trans-
ferred between fibroblasts and cancer cells although, in contrast to 
astrocytes, this cell type did not potentiate cancer cell survival in 
the presence of chemotherapies (27). Consequently, these results 
seem to be inconclusive regarding the dependence of the gene 
program induced in cancer cells by the influence of astrocytes. 
However, this point was partially clarified later when IL-6 and 
IL-8 production from cancer cells was shown to be dependent 
on the establishment of gap junctions with astrocytes (35). These 
cytokines influence both cancer cells and astrocytes, by inducing 
the expression of both endothelin receptors (ETAR and ETBR) 
on cancer cells and endothelin ligand (ET-1) on astrocytes (35) 
(Figure 1). Few of the initially deregulated genes upon cancer cell– 
astrocyte interaction were probed to be dependent on ET-1 (35). 
A number of these genes, including mesenchymal genes (TWIST1), 
inducers of resistance to stress (GSTA5), and antiapoptotic genes 
(BCL2L1), were validated in human brain metastasis (35). Based 
on these findings, they provided evidence that chemotherapeutic 
drugs including paclitaxel, 5-fluorouracil (5-FU), and cisplatin 
killed less cancer cells than when the gap junction inhibitor car-
benoxolone was added to cocultures or Cx43 was knocked down 
in astrocytes (27, 40). Yet, there were neither validations of the 
roles of these genes in vivo nor a molecular explanation on how 
gap junctions were established in the first place between the dif-
ferent cell types. Further, it remains to be seen whether the genes 
identified are main players in the brain metastasis phenotype. In 
contrast, the molecular mechanisms underlying the establish-
ment of gap junctions between cancer cells and RAs has been 
recently reported (9). A gene list initially reported as commonly 
deregulated in brain tropic cancer cells from lung and breast 
cancer, included the protocadherin 7 (PCDH7) (10). Besides 
brain metastatic cells, PCDH7 was also expressed in RAs in vitro 
and in vivo but not in other brain cell types (9). When PCDH7 
was downregulated from brain tropic cells, gap junction mediated 
transfer of calcein to RAs was severely impaired. Detailed analysis 
of the PCDH7-dependency of Cx43 mediated gap junction com-
munication probed that the protocadherin is required to establish 
gap junctions between cancer cells and astrocytes (Figure  1). 
Once the gap junction channel connects both cell types, they 
exchange at least two types of molecules that have been described 
in brain metastasis: the ion Ca2+ and the secondary messenger 
cGAMP. Calcium is usually exchanged between astrocytes within 
the neural network to synchronize their activity and coordinate 
their responses under homeostatic conditions (69). Cancer cells 
from multiple brain metastastasis models were shown to co-opt 
gap junction communication with astrocytes to reduce their 
excessive calcium load (Figure 1). Excessive amounts of calcium 
could be detrimental for cancer cells since it is a known trigger of 
DNA damage and inducer of apoptosis (71). As a consequence, a 
decrease in the intracellular concentration of calcium seems to be 
a requirement to maintain an aggressive brain colonization pat-
tern with marked resistance to chemotherapy. Intriguingly, use of 
gap junctions by cancer cells includes mechanisms reminiscent 
to antiviral cellular responses as shown previously (72, 73). 
Genomic instability is a frequent finding in advanced metastatic 
cancer (74) and as such has been reported in brain metastasis 
(75, 76). Although beneficial for cancer cells by boosting the gen-
eration of genetic variants that might be better fitted to colonize 
the brain, genomic instability also generates toxic byproducts 
such a double-stranded DNA (dsDNA) (77). Cytosolic dsDNA 
is sensed by cGAS which upon activation generates the second 
messenger cGAMP, driving an interferon response upon activa-
tion of STING (78). Transfer of cGAMP from cells infected with 
viruses to surrounding cells through Cx43 dependent gap junc-
tions was described as a mechanism to prevent viral expansion 
(79). Hence, brain metastatic cells have managed to co-opt and 
utilize this ancient molecular mechanisms for their own benefit. 
Initiated by the transfer of the second messenger to RAs, cGAMP 
activates STING at the endoplasmic reticulum, which leads to 
TBK1 mediated phosphorylation of IRF3 as described in other 
cellular contexts (78). Thereby, phosphorylated IRF3 enters the 
nuclei where it induces the expression and secretion of TNFα and 
INFα. These two cytokines in turn can activate NFκβ and STAT1 
in brain metastatic cells, which contributes to an increase in their 
proliferative potential and resistance to chemotherapeutic stress 
(9) (Figure  1). Interestingly, dsDNA is abundant in exosomes 
(80). Given the reported transfer of dsDNA between cells through 
exosomes in which the presence of Cx43 facilitates the entry into 
the recipient cell (81), additional mechanisms, which do not 
require juxtacrine, direct cell–cell contact, might also play a role 
in vivo.
iNFlUeNCe OF ASTROCYTeS  
ON NON-CANCeR CellS
As delineated above, astrocytes, as the most abundant cell type 
confined to the CNS, will statistically (by means of localization) 
account for a majority of the interactions that brain-homing 
clones of cancer cells will be exposed to during early but also late 
stages of brain metastasis. However, other cell types of the brain 
metastasis environment such as endothelial cells, pericytes and 
resident microglia as well as incoming myeloid cells (i.e., mac-
rophages) have been shown to interact and respond to the pres-
ence cancer cells (10, 17, 20, 22, 43, 58, 82, 83). Hence, astrocytes 
might also influence not only cancer cells but also other adjacent 
cell types in brain metastasis in a direct or indirect fashion. For 
example, astrocytes transfer exosome-enpacked microRNA-19a 
(miR-19a) to cancer cells. miR-19a silences the major tumor 
suppressor phosphatase and tensin homolog deleted on chro-
mosome 10 (PTEN) in cancer cells. As a result of this interaction 
a more favorable adaptation of cancer cells to the new tissue 
environment is achieved by increasing their growth rate but also 
by inducing the secretion of the chemokine (C-C motif) ligand 
2 (CCL2). Cancer cell secreted CCL2 participates in the genera-
tion of a protumorigenic niche by inducing an influx of brain 
metastasis-promoting Iba1+/CCR2+ myeloid cells. Importantly, 
higher CCL2 scores as determined by immunohistochemistry 
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were more frequently seen in brain metastatic tissue than in 
matched primary tumor tissue and additionally CCL2 expres-
sion correlated with PTEN loss in brain metastatic tissue (37). 
These results were corroborated by a more recent study (43). 
Although insights into astrocyte-mediated influence on other 
cell types in the context of brain metastasis is ill-defined, recent 
insights into phenotypic and genotypic signatures of astrocytes 
in other neurological diseases and other fields of neuroscience 
may aid in elucidating these potential implications in regard to 
brain metastasis (33). Emerging evidence has also reported the 
influence of RAs beyond the brain (84). Secretion of extracellular 
vesicles by RAs, including exosomes, could reach the systemic 
circulation in experimental models of inflammatory brain 
damage. Astrocyte-derived extracellular vesicles gain access to 
different organs (liver, lungs and spleen) where they induce an 
acute cytokine response characterized by the secretion of IL-17, 
IL-1β, IL-6, TNF-α, and CCL2. This acute cytokine response 
leads to the mobilization of Ly6b+ leukocytes that will infiltrate 
the brain to resolve the damage (84). Whether a similar mecha-
nism is occurring in brain metastasis remains to be addressed. 
Thus, future studies in brain metastasis should consider not only 
the local influence of RAs but also their potential contribution to 
other symptoms which might contribute to the deterioration of 
patient health state during brain metastasis (Table 1).
In contrast to RAs in other disease conditions such as stroke 
or traumatic brain injury, brain metastasis is a continuously 
progressing insult (i.e., growth and evolution of cancer cells). In 
this given context astrocytes are unable to resolve the insult and 
over time cancer cells hijack some of their functions and prompt-
ing to astrocytes to work for their own benefit. Thus, astrocytes 
convert to a dubious fellow companion to cancer cells aiding 
them in remodeling their new habitat, potentially influencing the 
behavior of other CNS cell types.
ASTROCYTe HeTeROgeNeiTY iN BRAiN 
MeTASTASiS
The brain is highly complex in respect to its cellular (and acellu-
lar) composition. The main cell type, the neuron, can be classified 
in two main classes (excitatory and inhibitory) and within them 
multiple subclasses are required to maintain the fine-tuning and 
wiring of neural circuits (85, 86). This complexity has remained 
exclusive to the neuronal compartment. However, evidence as to 
heterogeneity in non-neuronal components is steadily increasing. 
Recent findings have probed that subtypes of microglia reside 
in specific locations in the brain (87) which might be linked 
to subpopulations that emerge in and drive brain disorders of 
experimental models and humans (88). Astrocyte heterogeneity 
is of emerging interest given the potentially important implica-
tions in homeostasis (89–92) and disease (93–96). In brain 
metastasis in particular, a good body of evidence points toward 
opposite behaviors of astrocytes, which seem to be dependent on 
the disease stage. Initially, astrocytes act as a innate host defense 
system limiting the progression of the disease (10), while later on 
astrocytes favor it (9). Whether they belong to different subtypes 
of astrocytes or whether a consequence of the influence of cancer 
cells on them remains an issue of dispute. In view of the findings 
reported under homeostatic conditions and other CNS disorders, 
astrocytes are likely to include different subpopulations (48). 
Although heterogeneity in RAs associated with brain metastasis 
has not been formally probed, there are published observations 
that might be indicative of this possibility. During the coloniza-
tion of the brain RAs surround brain metastatic cells (9, 10, 12, 20, 
26). Besides GFAP other markers identifying this cell type have 
been reported in this glial cell type. However, these markers did 
not fully colocalize with each other, so that many GFAP+ RAs 
were negative for them, as in the case for Nestin. Nestin labels 
neural stem cells (97). The finding that Nestin is only present 
in a subset of RAs associated with brain metastasis (20) could 
suggest that heterogeneity among brain metastasis-associated 
astrocytes might have deeper implications at the functional level. 
In one study Xing et al. reported that Jagged1+ RAs were actively 
inducing Notch activity in brain metastatic cells (64). Again, the 
Jagged1 colocalization with GFAP was only partial (64), sug-
gesting that within the population of RAs there could be also a 
Jagged1-subset as well. The same applies to endothelin receptor, 
which has been shown to be present in a heterogeneous pattern 
among RAs in the context of brain metastasis (98). Interestingly, 
endothelin receptor and Notch have been reported in reactive 
astrocytes in other brain injuries (95, 99). A more unambigu-
ous example of the presence of RAs subpopulations associated 
with brain metastasis corresponds to the identification of p751-
PDGFRβ+ astrocytes (100). Phosphorylation of Tyr751 was used 
to label this subpopulation of RAs associated with brain metas-
tasis, preferentially located close to capillaries. This finding was 
expanded to human brain metastasis with breast and lung cancer. 
The inhibitor pazopanib, a multityrosine kinase inhibitor, includ-
ing PDGFRβ, was used to evaluate the functional implications of 
this subpopulation. Pazopanib used in vivo in experimental brain 
metastasis models significantly prevented their development. Yet, 
given the unspecific inhibitory nature of this inhibitor and the 
previous report showing that another pazopanib target present in 
cancer cells was required for brain metastasis, makes it difficult 
to conclude about the potential involvement of p751-PDGFRβ+ 
RAs in brain metastasis. Authors probed that the phosphorylation 
of the PDGFRβ receptor in astrocytes was induced upon cocul-
ture with brain metastatic cancer cells, indicating that PDGFRβ+ 
RAs might represent a brain metastasis-specific subpopulation 
(Table 1).
Consequently, exploiting the molecular characterization of 
brain metastasis-associated RAs is an emerging area of research 
that will facilitate the understanding of their biology and which 
could also offer innovative ways to target this particular condition.
geNOMiCS AND SigNAliNg PATHwAYS 
iN BRAiN MeTASTASiS-ASSOCiATeD 
ASTROCYTeS
In contrast to existing examples in cancer cells (9, 40, 68) 
(Figure  2), there are no genomic data regarding RAs associ-
ated with brain metastasis. Instead, several publications have 
reported specific signaling pathways to be involved in the 
crosstalk (Figure  1). A reactive astrocytic phenotype observed 
in a melanoma brain metastasis model (51) was linked to an 
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earlier proposed gene signature for RAs in stroke or LPS treat-
ment (32). Although the authors did not undertake an unbiased 
astrocyte-specific profiling in their experiments gliosis-related 
genes such as Gfap, Cxcl10, Lcn-2, Serpina3n, Serpine1, and 
Timp-1 were significantly upregulated in the group of mice in 
which melanoma cells were coinjected together with astrocytes 
as compared to melanoma cells injected alone (51). Besides these 
gene expression changes additional signaling pathways have been 
reported (Figure  1) including Cx43/cGAS/TBK1/IRF3/IFNα.
TNF (9), IL-6.IL-8/ET-1 (35), IL1B/IL1RA/HGF.JAG1 (63, 64). 
Increasing numbers of genomic studies on astrocytes are being 
performed in other neurological disorders (32, 52, 90) which will 
be an extraordinary repository for comparative analyses between 
different brain disorders to interrogate common and different 
aspects of the underlying biology of RAs in different scenarios 
as well as to evaluate the possibility to apply drug repurposing 
(Table 1).
ASTROCYTe-BASeD THeRAPieS
Although limited in number, some studies have tested the 
impact of targeting certain aspects of RAs associated with brain 
metastasis. Since these therapeutic efforts are aimed to block pro-
metastatic components of the microenvironment, they have been 
applied to advanced stages of the disease. All of these preclinical 
studies have shown great potential thus opening the possibility of 
treating brain metastasis by targeting the microenvironment (9, 
98, 100). In principle, these innovative therapies might be applied 
to a broader number of patients, given that all brain metastases 
harbour RAs associated independently of the source of the 
primary tumor. Such therapies might also involve less secondary 
effects, given that the target will not be attributed to normal brain 
tissue.
Macitentan
Macitentan is a FDA-approved BBB permeable inhibitor targeting 
endothelin receptor A and B (101) that is being used for treat-
ment of pulmonary arterial hypertension. Macitentan has been 
repurposed to evaluate its potential effect in primary and sec-
ondary experimental brain tumor models (98, 102). Treatment of 
established experimental brain metastasis from lung (PC-14) and 
breast cancer (MDA231) in the preventive (micrometastasis) and 
interventional (macrometastasis) settings dramatically reduced 
brain metastasis and increased survival in mice, but only when 
combined with chemotherapy (Paclitaxel). Since these recep-
tors are also present in cancer cells and endothelial cells, the 
therapeutic benefit cannot be assigned to targeting RAs alone. 
Nevertheless, given the contribution of astrocytes to endothelin 
receptor signaling (35) a part of it might be derived by the inhibi-
tory effect in astrocytes. Although Macitentan alone induced a 
massive reduction in pAKT and pMAPK, this did not translate 
into a detectable phenotype with non-invasive bioluminescence 
monitoring. However, combination with Paclitaxel dramatically 
decreased the number of tumor-associated vessels, limiting the 
access of nutrients to cancer cells, which suffer from massive 
induction in cleaved caspase 3. Interestingly, initially described 
genes upregulated in cancer cells upon coculture with astrocytes 
(BCL2L1, GSTA5, and TWIST1) (27) were downregulated by 
Macitentan alone.
Given the finding of a similar phenotype in glioma models, a 
key contribution of the endothelin axis in brain tumors seems to 
be probable. The clinical trial initiated in recurrent glioma based 
on these findings (NCT01499251) was concluded recently and 
results should be publicly available soon. If positive results being 
reported, this therapeutic effort should be extended to brain 
metastasis patients.
gap Junction inhibitors
Gap junction intercellular communication (GJIC) is more and 
more seen as a potential target in different disease conditions 
such as different heart pathologies, seizures and cancer (103). 
There is a good amount of in vitro studies dedicated toward the 
characterization of pharmacological modulators of GJIC either 
via acute uncoupling or enhancement of signaling or their influ-
ence on gene expression, biosynthesis and turnover (103). Yet, 
until recently there have been only a few studies published on the 
potential usefulness of inhibition of GJIC in the setting of brain 
metastasis (27, 40). Initial work probed the protective effect of 
astrocytes against different chemotherapeutic drugs used in the 
clinic (paclitaxel, cisplatin, and 5-FU) on different melanoma cell 
lines in vitro (40). Inhibition of GJC channels pharmacologically 
by using the pan-Cx inhibitor carbenoloxone (CBX) or geneti-
cally by knocking down gap junctions in astrocytes during cocul-
turing of cancer cells with astrocytes was able to render cancer 
cells chemosensitive (40). The therapeutic value of targeting gap 
junctions in experimental brain metastasis models was recently 
reported (9). Instead of CBX the authors used two drugs for 
this purpose: the anti-inflammatory compound meclofenamate, 
which was previously shown to inhibit Cx43 gap junction gating 
(104), and the benzopyrane derivative tonabersat, which was pre-
viously shown to have specific activity for binding to astrocytes 
and inhibit gap-junction-mediated processes (105–107). Both 
were used in brain-related disorders before (107, 108) and are 
FDA approved. The use of either meclofenamate or tonabersat in 
breast or lung brain metastasis from human or mouse cancer cells 
induced a significant decrease in brain tumor burden even after 
metastatic cells have seed and grew in this organ (9). Interestingly, 
given the brain specific mechanism targeted, none of the drugs 
show any effect when applied to orthotopic injections in the breast 
or in the lung (9). Based on these results an ongoing clinical trial 
(NCT02429570) has been launched to apply meclofenamate to 
recurring or progressing brain metastasis from multiple primary 
tumors.
Pazopanib
This orally bioavailable multiple tyrosine kinase inhibitor target-
ing VEGFR1–3, PDGFRα-β, c-kit, and B-Raf was initially found 
to target cancer cells in experimental HER2+ brain metastasis 
models (109). Later it was found that it also decreases tyrosine 
phosphorylation of PDGFRβ in RAs present in lung and breast 
cancer brain metastasis, as well as from astrocyte primary 
cultures obtained from craniotomies of five patients with brain 
metastases. As with Macitentan, the specific contribution of 
inhibition of astrocyte PDGFRβ receptor is not known. Thus, in 
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order to conclude about the contribution of this therapy, more 
specific genetic strategies targeting PDGFRβ in RAs are necessary. 
However, the ability of pazopanib to decrease the phosphoryla-
tion of the PDGFRβ receptor in astrocytes was correlated with 
reduced proliferative capacity of an immortalized astrocyte cell 
line (100). In vivo, targeting of Tyr phosphorylation of PDGFRβ 
did not decrease the GFAP population of RAs suggesting that 
pazopanib targets PDGFRβ+ RAs without killing them.
Compound e
As brain metastatic cancer cells co-opt physiological pathways 
to adapt to and to thrive within the CNS, the same applies to 
the acquisition of a stemness phenotype (64). RAs are involved 
in the regulation of the cancer stem-like cell phenotype in a 
Notch-dependent manner (64). Subsequently, Compound E, a 
gamma secretase inhibitor, has shown to impair the interaction 
between the astrocytic Jagged1 and cancer cells expressing Notch 
(64). When Compound E was administered to mice injected 
with a triple negative breast cancer model metastatic to the brain 
(MDA231-BrM) a significant decrease in the growth of cancer 
cells was observed (64).
lenalidomide
Currently, no predictive biomarkers are clinically available to help 
in identifying those cancer patients which likely will experience 
brain metastasis during the course of their disease. Ongoing efforts 
to identify brain metastasis biomarkers found FN14 as a gene dif-
ferentially expressed in brain metastasis as compared to primary 
tumors (110). This finding was later validated in a multicenter 
study involving 318 breast cancer patients, in which 138 devel-
oped brain metastases (13). Intriguingly, the presence of FN14, 
a TNFR family receptor member, in primary breast tumors was 
associated with a 5.24-fold increase in brain metastasis incidence 
(13). FN14 ligands include astrocyte growth factors TWEAK 
and TNF-alpha, where the former is mainly produced by astro-
cytes and microglial cells in the CNS (13, 111). Tackling FN14/
TWEAK axis by using the thalidomide derivative lenalidomide 
(LND) impaired brain metastasis presumably through an effect 
on RA reactivity (13). Based on its anti-inflammatory properties 
demonstrated in other CNS conditions such as multiple sclerosis 
and the relative success of lenalidomide used in the framework 
of a first line regimen for multiple myeloma, upcoming studies 
should verify the reported beneficial effect in targeting brain 
metastasis, possibly in combination with other first line drugs.
DiSCUSSiON
Whilst brain metastasis remains a major threat to cancer patients, 
its annual incidence being on the rise, extracranial disease is 
becoming targeted more and more efficiently owing to the 
advent of molecular therapeutics as exemplified most recently 
by immune checkpoint inhibitors (112). New insights deriving 
from in vitro and in vivo preclinical models of brain metastasis 
have enabled researchers to have a more precise picture of the 
biology of coevolution of brain colonizing cancer cells and 
their surrounding microenvironment, per  se offering ways for 
therapeutic exploitation. By analogy with insights derived from 
the field of neuroinflammation and neurodegeneration, where 
RAs are increasingly seen as main disease elements by means 
of modulating neurotoxic effects via non-cell autonomous 
mechanisms, more in-depth and comprehensive characterization 
of the RA phenotype on a genomic or proteomic scale in brain 
metastasis [employing techniques such as population or single 
cell RNA-seq, TRAP, or MS-based proteome analysis (32, 33, 
52, 90)] might soon become a reality and enable researchers to 
validate potential candidates in brain metastasis models. It would 
be interesting to determine whether there is a difference, and if 
yes to what extent RAs found in brain metastasis distinguish 
from their counterparts seen in other disease conditions (32, 
33, 52). Additionally, insights into the role of specific astrocyte 
subpopulations, their evolution during disease progression as 
well as their manipulation would provide a valuable means of 
targeting astrocyte-cancer cell interactions. Importantly, one 
must ask whether there is any specific therapeutic window as to 
which time point during brain metastasis might represent the 
most effective way of modulating and targeting this vicious cross-
talk or even promote the antimetastatic behavior of RAs. Taken 
together, insights gained from recent research have undoubtedly 
put astrocytes in brain metastasis into perspective turning them 
from passive bystanders to active key players in brain metastasis.
In addition to that, new avenues of research will allow studying 
RAs in brain metastasis on a more systemic scale, an aspect which 
is believed to be underestimated in the context of gliosis in other 
CNS diseases such as infectious diseases, where proinflammatory 
molecules released from peripheral tissue sites of infection likely 
influence far-distant RAs (28). Interestingly, emerging studies 
have proposed the influence of the primary tumor on the brain 
environment facilitating the colonization of cancer cells (113, 
114). The systemic influence of RAs in models of neuroinflamma-
tion has been also reported (84, 115). Given the strong response 
of RAs to brain metastasis during the course of brain coloniza-
tion, it is temping to speculate that the identification of secreted 
molecules might represent putative biomarkers of early diagnosis 
or response to therapy, even more if specific prometastatic sub-
populations of RAs could be identified to be targeted.
In sum, RAs are largely involved in reciprocal interactions 
with metastatic cells and govern distinct cancer cell phenotypic 
features required during the process of colonization such as 
invasive capacity, survival and stemness. The focus of future 
studies will likely shift toward the specific makeup of the brain 
microenvironment appreciating its complexity and heterogeneity 
as well as its role to serve as a putative future therapeutic target 
in combating brain metastasis more efficiently and successfully 
(Table 1).
AUTHOR CONTRiBUTiONS
MV, NP, and DW conceptualized the work and wrote the manu-
script. CF-T performed the bioinformatic analysis.
ACKNOwleDgMeNTS
We acknowledge members of the Brain Metastasis Group for 
critically reading the manuscript.
10
Wasilewski et al. RA in Brain Metastasis
Frontiers in Oncology | www.frontiersin.org December 2017 | Volume 7 | Article 298
FUNDiNg
This work was supported by MINECO grants MINECO-
Retos SAF2014-57243-R (MV), MINECO-Europa Excelencia 
SAF2015-62547-ERC (MV), IX FERO Grant for Research in 
Oncology (MV), and Bristol-Myers Squibb-Melanoma Research 
Alliance Young Investigator Award 498103 (MV). MV is a Ramón 
y Cajal Investigator (RYC-2013-13365).
ReFeReNCeS
1. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysi-
ology. J Neurooncol (2005) 75:5–14. doi:10.1007/s11060-004-8093-6 
2. Boire A, Zou Y, Shieh J, Macalinao DG, Pentsova E, Massagué J. Complement 
component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. 
Cell (2017) 168:1101–13.e13. doi:10.1016/j.cell.2017.02.025 
3. Maher EA, Mietz J, Arteaga CL, DePinho RA, Mohla S. Brain metastasis: 
opportunities in basic and translational research. Cancer Res (2009) 69: 
6015–20. doi:10.1158/0008-5472.CAN-08-4347 
4. Costa DB, Shaw AT, Ou S-HI, Solomon BJ, Riely GJ, Ahn M-J, et al. Clinical 
experience with crizotinib in patients with advanced ALK-rearranged non-
small-cell lung cancer and brain metastases. J Clin Oncol (2015) 33:1881–8. 
doi:10.1200/JCO.2014.59.0539 
5. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and 
therapeutic targets. Nat Rev Cancer (2011) 11:352–63. doi:10.1038/nrc3053 
6. Osswald M, Blaes J, Liao Y, Solecki G, Gömmel M, Berghoff AS, et al. Impact 
of blood-brain barrier integrity on tumor growth and therapy response in 
brain metastases. Clin Cancer Res (2016) 22:6078–87. doi:10.1158/1078-0432.
CCR-16-1327 
7. Stemmler H-J, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. 
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in 
HER2-positive breast cancer patients with brain metastases and impairment 
of blood-brain barrier. Anticancer Drugs (2007) 18:23–8. doi:10.1097/01.cad. 
0000236313.50833.ee 
8. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The 
biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 
(2011) 8:344–56. doi:10.1038/nrclinonc.2011.58 
9. Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, et al. Carcinoma-
astrocyte gap junctions promote brain metastasis by cGAMP transfer. 
Nature (2016) 533:493–8. doi:10.1038/nature18268 
10. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH-F, Lee DJ, et al. Serpins 
promote cancer cell survival and vascular co-option in brain metastasis. 
Cell (2014) 156:1002–16. doi:10.1016/j.cell.2014.01.040 
11. Bos PD, Zhang XH-F, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes 
that mediate breast cancer metastasis to the brain. Nature (2009) 459:1005–9. 
doi:10.1038/nature08021 
12. Nguyen DX, Chiang AC, Zhang XH-F, Kim JY, Kris MG, Ladanyi M, et al. 
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarci-
noma metastasis. Cell (2009) 138:51–62. doi:10.1016/j.cell.2009.04.030 
13. Martínez-Aranda A, Hernández V, Guney E, Muixí L, Foj R, Baixeras N, 
et  al. FN14 and GRP94 expression are prognostic/predictive biomarkers of 
brain metastasis outcome that open up new therapeutic strategies. Oncotarget 
(2015) 6:44254–73. doi:10.18632/oncotarget.5471 
14. Li B, Wang C, Zhang Y, Zhao XY, Huang B, Wu PF, et  al. Elevated PLGF 
contributes to small-cell lung cancer brain metastasis. Oncogene (2013) 
32:2952–62. doi:10.1038/onc.2012.313 
15. Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, et al. 
PLEKHA5 as a biomarker and potential mediator of melanoma brain 
metastasis. Clin Cancer Res (2015) 21:2138–47. doi:10.1158/1078-0432.
CCR-14-0861 
16. Wrage M, Hagmann W, Kemming D, Uzunoglu FG, Riethdorf S, 
Effenberger K, et al. Identification of HERC5 and its potential role in NSCLC 
progression. Int J Cancer (2015) 136:2264–72. doi:10.1002/ijc.29298 
17. Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, et  al. 
Analysis of tumour- and stroma-supplied proteolytic networks reveals 
a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol (2014) 
16:876–88. doi:10.1038/ncb3011 
18. Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, et  al.  
AKT1 activation promotes development of melanoma metastases. Cell Rep 
(2015) 13:898–905. doi:10.1016/j.celrep.2015.09.057 
19. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WEF, Goldbrunner R, 
Herms J, et al. Real-time imaging reveals the single steps of brain metastasis 
formation. Nat Med (2010) 16:116–22. doi:10.1038/nm.2072 
20. Lorger M, Felding-Habermann B. Capturing changes in the brain microen-
vironment during initial steps of breast cancer brain metastasis. Am J Pathol 
(2010) 176:2958–71. doi:10.2353/ajpath.2010.090838 
21. Pukrop T, Dehghani F, Chuang H-N, Lohaus R, Bayanga K, Heermann S, 
et  al. Microglia promote colonization of brain tissue by breast cancer cells 
in a Wnt-dependent way. Glia (2010) 58:1477–89. doi:10.1002/glia.21022 
22. Louie E, Chen XF, Coomes A, Ji K, Tsirka S, Chen EI. Neurotrophin-3 mod-
ulates breast cancer cells and the microenvironment to promote the growth 
of breast cancer brain metastasis. Oncogene (2013) 32:4064–77. doi:10.1038/
onc.2012.417 
23. Brantley EC, Guo L, Zhang C, Lin Q, Yokoi K, Langley RR, et  al. Nitric 
oxide-mediated tumoricidal activity of murine microglial cells. Transl Oncol 
(2010) 3:380–8. doi:10.1593/tlo.10208 
24. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar 
formation. Trends Neurosci (2009) 32:638–47. doi:10.1016/j.tins.2009.08.002 
25. Liddelow SA, Barres BA. Reactive astrocytes: production, function, and 
therapeutic potential. Immunity (2017) 46:957–67. doi:10.1016/j.immuni. 
2017.06.006 
26. Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, et  al. 
Reactive glia are recruited by highly proliferative brain metastases of breast 
cancer and promote tumor cell colonization. Clin Exp Metastasis (2008) 
25:799–810. doi:10.1007/s10585-008-9193-z 
27. Kim S-J, Kim J-S, Park ES, Lee J-S, Lin Q, Langley RR, et al. Astrocytes upreg-
ulate survival genes in tumor cells and induce protection from chemotherapy. 
Neoplasia (2011) 13:286–98. doi:10.1593/neo.11112 
28. Burda JE, Sofroniew MV. Reactive gliosis and the multicellular response to 
CNS damage and disease. Neuron (2014) 81:229–48. doi:10.1016/j.neuron. 
2013.12.034 
29. Wanner IB, Anderson MA, Song B, Levine J, Fernandez A, Gray-Thompson Z, 
et al. Glial scar borders are formed by newly proliferated, elongated astrocytes 
that interact to corral inflammatory and fibrotic cells via STAT3-dependent 
mechanisms after spinal cord injury. J Neurosci (2013) 33:12870–86. 
doi:10.1523/JNEUROSCI.2121-13.2013 
30. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci  
(2004) 5:146–56. doi:10.1038/nrn1326 
31. Hara M, Kobayakawa K, Ohkawa Y, Kumamaru H, Yokota K, Saito T, et al. 
Interaction of reactive astrocytes with type I collagen induces astrocytic scar 
formation through the integrin-N-cadherin pathway after spinal cord injury. 
Nat Med (2017) 23:818–28. doi:10.1038/nm.4354 
32. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, et al. Genomic 
analysis of reactive astrogliosis. J Neurosci (2012) 32:6391–410. doi:10.1523/
JNEUROSCI.6221-11.2012 
33. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, 
et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 
(2017) 541:481–7. doi:10.1038/nature21029 
34. Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat 
Neurosci (2016) 19:987–91. doi:10.1038/nn.4338 
35. Kim SW, Choi HJ, Lee H-J, He J, Wu Q, Langley RR, et al. Role of the endo-
thelin axis in astrocyte- and endothelial cell-mediated chemoprotection of 
cancer cells. Neuro Oncol (2014) 16:1585–98. doi:10.1093/neuonc/nou128 
36. Choy C, Ansari KI, Neman J, Hsu S, Duenas MJ, Li H, et al. Cooperation of 
neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain 
metastases. Breast Cancer Res (2017) 19:51. doi:10.1186/s13058-017-0844-3 
37. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang W-C, et  al. Micro-
environment-induced PTEN loss by exosomal microRNA primes brain 
metastasis outgrowth. Nature (2015) 527:100–4. doi:10.1038/nature15376 
38. Stevens LE, Cheung WK, Adua SJ, Arnal-Estapé A, Zhao M, Liu Z, et  al. 
Extracellular matrix receptor expression in subtypes of lung adenocarcinoma 
11
Wasilewski et al. RA in Brain Metastasis
Frontiers in Oncology | www.frontiersin.org December 2017 | Volume 7 | Article 298
potentiates outgrowth of micrometastases. Cancer Res (2017) 77(8):1905–17. 
doi:10.1158/0008-5472.CAN-16-1978 
39. Seike T, Fujita K, Yamakawa Y, Kido MA, Takiguchi S, Teramoto N, et  al. 
Interaction between lung cancer cells and astrocytes via specific inflammatory 
cytokines in the microenvironment of brain metastasis. Clin Exp Metastasis 
(2011) 28:13–25. doi:10.1007/s10585-010-9354-8 
40. Lin Q, Balasubramanian K, Fan D, Kim S-J, Guo L, Wang H, et al. Reactive 
astrocytes protect melanoma cells from chemotherapy by sequestering intra-
cellular calcium through gap junction communication channels. Neoplasia 
(2010) 12:748–54. doi:10.1593/neo.10602 
41. Langley RR, Fan D, Guo L, Zhang C, Lin Q, Brantley EC, et al. Generation of 
an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role 
of astrocytes in brain metastasis. Int J Oncol (2009) 35:665–72. doi:10.3892/
ijo_00000378 
42. Mendes O, Kim H-T, Lungu G, Stoica G. MMP2 role in breast cancer brain 
metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp 
Metastasis (2007) 24:341–51. doi:10.1007/s10585-007-9071-0 
43. Hohensee I, Chuang H-N, Grottke A, Werner S, Schulte A, Horn S, et  al.  
PTEN mediates the cross talk between breast and glial cells in brain metas-
tases leading to rapid disease progression. Oncotarget (2017) 8:6155–68. 
doi:10.18632/oncotarget.14047 
44. McCarthy KD, de Vellis J. Preparation of separate astroglial and oligoden-
droglial cell cultures from rat cerebral tissue. J Cell Biol (1980) 85:890–902. 
doi:10.1083/jcb.85.3.890 
45. Foo LC, Allen NJ, Bushong EA, Ventura PB, Chung W-S, Zhou L, et  al. 
Development of a method for the purification and culture of rodent astrocytes. 
Neuron (2011) 71:799–811. doi:10.1016/j.neuron.2011.07.022 
46. Soreq L; UK Brain Expression Consortium, North American Brain Expression 
Consortium, Rose J, Soreq E, Hardy J, et  al. Major shifts in glial regional 
identity are a transcriptional hallmark of human brain aging. Cell Rep (2017) 
18:557–70. doi:10.1016/j.celrep.2016.12.011 
47. Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, et al. 
Purification and characterization of progenitor and mature human astro-
cytes reveals transcriptional and functional differences with mouse. Neuron  
(2016) 89:37–53. doi:10.1016/j.neuron.2015.11.013 
48. Anderson MA, Ao Y, Sofroniew MV. Heterogeneity of reactive astrocytes. 
Neurosci Lett (2014) 565:23–9. doi:10.1016/j.neulet.2013.12.030 
49. Chuang H-N, van Rossum D, Sieger D, Siam L, Klemm F, Bleckmann A, et al. 
Carcinoma cells misuse the host tissue damage response to invade the brain. 
Glia (2013) 61:1331–46. doi:10.1002/glia.22518 
50. Dezonne RS, Sartore RC, Nascimento JM, Saia-Cereda VM, Romão LF, 
Alves-Leon SV, et al. Derivation of functional human astrocytes from cerebral 
organoids. Sci Rep (2017) 7:45091. doi:10.1038/srep45091 
51. Schwartz H, Blacher E, Amer M, Livneh N, Abramovitz L, Klein A, et  al. 
Incipient melanoma brain metastases instigate astrogliosis and neuroin-
flammation. Cancer Res (2016) 76:4359–71. doi:10.1158/0008-5472.CAN- 
16-0485 
52. Anderson MA, Burda JE, Ren Y, Ao Y, O’Shea TM, Kawaguchi R, et  al. 
Astrocyte scar formation aids central nervous system axon regeneration. 
Nature (2016) 532:195–200. doi:10.1038/nature17623 
53. Srinivasan R, Lu T-Y, Chai H, Xu J, Huang BS, Golshani P, et al. New trans-
genic mouse lines for selectively targeting astrocytes and studying calcium 
signals in astrocyte processes in situ and in vivo. Neuron (2016) 92:1181–95. 
doi:10.1016/j.neuron.2016.11.030 
54. Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A, 
et al. Cre-dependent selection yields AAV variants for widespread gene trans-
fer to the adult brain. Nat Biotechnol (2016) 34:204–9. doi:10.1038/nbt.3440 
55. Figueres-Oñate M, García-Marqués J, López-Mascaraque L. UbC-StarTrack, 
a clonal method to target the entire progeny of individual progenitors. 
Sci Rep (2016) 6:33896. doi:10.1038/srep33896 
56. Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, et al. Transgenic 
mouse model for skin malignant melanoma. Oncogene (1998) 17:1885–8. 
doi:10.1038/sj.onc.1202077 
57. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. 
Induction of small cell lung cancer by somatic inactivation of both Trp53 and 
Rb1 in a conditional mouse model. Cancer Cell (2003) 4:181–9. doi:10.1016/
S1535-6108(03)00220-4 
58. Lyle LT, Lockman PR, Adkins CE, Mohammad AS, Sechrest E, Hua E, 
et  al. Alterations in pericyte subpopulations are associated with elevated 
blood-tumor barrier permeability in experimental brain metastasis of 
breast cancer. Clin Cancer Res (2016) 22:5287–99. doi:10.1158/1078-0432.
CCR-15-1836 
59. Pencheva N, Buss CG, Posada J, Merghoub T, Tavazoie SF. Broad-spectrum 
therapeutic suppression of metastatic melanoma through nuclear hormone 
receptor activation. Cell (2014) 156:986–1001. doi:10.1016/j.cell.2014.01.038 
60. Morsi A, Gaziel-Sovran A, Cruz-Munoz W, Kerbel RS, Golfinos JG, 
Hernando E, et al. Development and characterization of a clinically relevant 
mouse model of melanoma brain metastasis. Pigment Cell Melanoma Res 
(2013) 26:743–5. doi:10.1111/pcmr.12114 
61. Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, et  al. Metastatic 
latency and immune evasion through autocrine inhibition of WNT. Cell 
(2016) 165:45–60. doi:10.1016/j.cell.2016.02.025 
62. Wu K, Fukuda K, Xing F, Zhang Y, Sharma S, Liu Y, et al. Roles of the cyclo-
oxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast 
cancer. J Biol Chem (2015) 290:9842–54. doi:10.1074/jbc.M114.602185 
63. Xing F, Liu Y, Sharma S, Wu K, Chan MD, Lo H-W, et al. Activation of the 
c-Met pathway mobilizes an inflammatory network in the brain microen-
vironment to promote brain metastasis of breast cancer. Cancer Res (2016) 
76:4970–80. doi:10.1158/0008-5472.CAN-15-3541 
64. Xing F, Kobayashi A, Okuda H, Watabe M, Pai SK, Pandey PR, et al. Reactive 
astrocytes promote the metastatic growth of breast cancer stem-like cells 
by activating Notch signalling in brain. EMBO Mol Med (2013) 5:384–96. 
doi:10.1002/emmm.201201623 
65. Klein A, Schwartz H, Sagi-Assif O, Meshel T, Izraely S, Ben Menachem S, 
et al. Astrocytes facilitate melanoma brain metastasis via secretion of IL-23. 
J Pathol (2015) 236:116–27. doi:10.1002/path.4509 
66. Lee JY, Park K, Lee E, Ahn T, Jung HH, Lim SH, et al. Gene expression pro-
filing of breast cancer brain metastasis. Sci Rep (2016) 6:28623. doi:10.1038/
srep28623 
67. Wang L, Cossette SM, Rarick KR, Gershan J, Dwinell MB, Harder DR, et al. 
Astrocytes directly influence tumor cell invasion and metastasis in vivo. PLoS 
One (2013) 8(12):e80933. doi:10.1371/journal.pone.0080933
68. Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, et  al. 
Estrogen promotes the brain metastatic colonization of triple negative breast 
cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene (2016) 
35:2881–92. doi:10.1038/onc.2015.353 
69. Giaume C, Koulakoff A, Roux L, Holcman D, Rouach N. Astroglial networks: 
a step further in neuroglial and gliovascular interactions. Nat Rev Neurosci 
(2010) 11:87–99. doi:10.1038/nrn2757 
70. Oberheim NA, Tian G-F, Han X, Peng W, Takano T, Ransom B, et al. Loss 
of astrocytic domain organization in the epileptic brain. J Neurosci (2008) 
28:3264–76. doi:10.1523/JNEUROSCI.4980-07.2008 
71. Roderick HL, Cook SJ. Ca2+ signalling checkpoints in cancer: remodelling 
Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer (2008) 
8:361–75. doi:10.1038/nrc2374 
72. Gentili M, Kowal J, Tkach M, Satoh T, Lahaye X, Conrad C, et al. Transmis-
sion of innate immune signaling by packaging of cGAMP in viral particles. 
Science (2015) 349:1232–6. doi:10.1126/science.aab3628 
73. Bridgeman A, Maelfait J, Davenne T, Partridge T, Peng Y, Mayer A, et  al. 
Viruses transfer the antiviral second messenger cGAMP between cells. 
Science (2015) 349:1228–32. doi:10.1126/science.aab3632 
74. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability – an evolving 
hallmark of cancer. Nat Rev Mol Cell Biol (2010) 11:220–8. doi:10.1038/nrm2858 
75. Woditschka S, Evans L, Duchnowska R, Reed LT, Palmieri D, Qian Y, et al. 
DNA double-strand break repair genes and oxidative damage in brain metasta-
sis of breast cancer. J Natl Cancer Inst (2014) 106:1–13. doi:10.1093/jnci/dju145 
76. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, 
et  al. Genomic characterization of brain metastases reveals branched evo-
lution and potential therapeutic targets. Cancer Discov (2015) 5:1164–77. 
doi:10.1158/2159-8290.CD-15-0369 
77. Srivastava M, Raghavan SC. DNA double-strand break repair inhibitors as 
cancer therapeutics. Chem Biol (2015) 22:17–29. doi:10.1016/j.chembiol. 
2014.11.013 
78. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, et  al. Cyclic GMP-AMP is an 
endogenous second messenger in innate immune signaling by cytosolic 
DNA. Science (2013) 339:826–30. doi:10.1126/science.1229963 
79. Ablasser A, Schmid-Burgk JL, Hemmerling I, Horvath GL, Schmidt T, 
Latz E, et  al. Cell intrinsic immunity spreads to bystander cells via the 
12
Wasilewski et al. RA in Brain Metastasis
Frontiers in Oncology | www.frontiersin.org December 2017 | Volume 7 | Article 298
intercellular transfer of cGAMP. Nature (2013) 503:530–4. doi:10.1038/
nature12640 
80. Kalluri R, LeBleu VS. Discovery of double-stranded genomic DNA in cir-
culating exosomes. Cold Spring Harb Symp Quant Biol (2016) 81:275–80. 
doi:10.1101/sqb.2016.81.030932 
81. Soares AR, Martins-Marques T, Ribeiro-Rodrigues T, Ferreira JV, Catarino S, 
Pinho MJ, et  al. Gap junctional protein Cx43 is involved in the communi-
cation between extracellular vesicles and mammalian cells. Sci Rep (2015) 
5:13243. doi:10.1038/srep13243 
82. Rippaus N, Taggart D, Williams J, Andreou T, Wurdak H, Wronski K, et al. 
Metastatic site-specific polarization of macrophages in intracranial breast 
cancer metastases. Oncotarget (2016) 7:41473–87. doi:10.18632/oncotarget. 
9445 
83. Siam L, Bleckmann A, Chaung H-N, Mohr A, Klemm F, Barrantes-Freer A, 
et  al. The metastatic infiltration at the metastasis/brain parenchyma- 
interface is very heterogeneous and has a significant impact on survival in a pro-
spective study. Oncotarget (2015) 6:29254–67. doi:10.18632/oncotarget.4201 
84. Dickens AM, Tovar-Y-Romo LB, Yoo S-W, Trout AL, Bae M, Kanmogne M, 
et al. Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte 
response to inflammatory brain lesions. Sci Signal (2017) 10(473):eaai7696. 
doi:10.1126/scisignal.aai7696 
85. Custo Greig LF, Woodworth MB, Galazo MJ, Padmanabhan H, Macklis JD. 
Molecular logic of neocortical projection neuron specification, development 
and diversity. Nat Rev Neurosci (2013) 14:755–69. doi:10.1038/nrn3586 
86. DeFelipe J, López-Cruz PL, Benavides-Piccione R, Bielza C, Larrañaga P, 
Anderson S, et  al. New insights into the classification and nomenclature 
of cortical GABAergic interneurons. Nat Rev Neurosci (2013) 14:202–16. 
doi:10.1038/nrn3444 
87. Prinz M, Erny D, Hagemeyer N. Ontogeny and homeostasis of CNS 
myeloid cells. Nat Immunol (2017) 18:385–92. doi:10.1038/ni.3703 
88. Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, 
Ulland TK, et al. A unique microglia type associated with restricting devel-
opment of Alzheimer’s disease. Cell (2017) 169:1276–90.e17. doi:10.1016/ 
j.cell.2017.05.018 
89. Ben Haim L, Rowitch DH. Functional diversity of astrocytes in neural circuit 
regulation. Nat Rev Neurosci (2017) 18:31–41. doi:10.1038/nrn.2016.159 
90. Chai H, Diaz-Castro B, Shigetomi E, Monte E, Octeau JC, Yu X, et al. Neural 
circuit-specialized astrocytes: transcriptomic, proteomic, morphological, 
and functional evidence. Neuron (2017) 95:531–49.e9. doi:10.1016/j.neuron. 
2017.06.029 
91. Tsai H-H, Li H, Fuentealba LC, Molofsky AV, Taveira-Marques R, Zhuang H, 
et al. Regional astrocyte allocation regulates CNS synaptogenesis and repair. 
Science (2012) 337:358–62. doi:10.1126/science.1222381 
92. Martín R, Bajo-Grañeras R, Moratalla R, Perea G, Araque A. Circuit-specific 
signaling in astrocyte-neuron networks in basal ganglia pathways. Science 
(2015) 349:730–4. doi:10.1126/science.aaa7945 
93. Bardehle S, Krüger M, Buggenthin F, Schwausch J, Ninkovic J, Clevers H, 
et al. Live imaging of astrocyte responses to acute injury reveals selective jux-
tavascular proliferation. Nat Neurosci (2013) 16:580–6. doi:10.1038/nn.3371 
94. Ben Haim L, Ceyzériat K, Carrillo-de Sauvage MA, Aubry F, Auregan G, 
Guillermier M, et al. The JAK/STAT3 pathway is a common inducer of astro-
cyte reactivity in Alzheimer’s and Huntington’s diseases. J Neurosci (2015) 
35:2817–29. doi:10.1523/JNEUROSCI.3516-14.2015 
95. LeComte MD, Shimada IS, Sherwin C, Spees JL. Notch1-STAT3-ETBR 
signaling axis controls reactive astrocyte proliferation after brain injury. 
Proc Natl Acad Sci U S A (2015) 112:8726–31. doi:10.1073/pnas.1501029112 
96. Booth HDE, Hirst WD, Wade-Martins R. The role of astrocyte dysfunction 
in Parkinson’s disease pathogenesis. Trends Neurosci (2017) 40:358–70. 
doi:10.1016/j.tins.2017.04.001 
97. Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new 
class of intermediate filament protein. Cell (1990) 60:585–95. doi:10.1016/ 
0092-8674(90)90662-X 
98. Lee HJ, Hanibuchi M, Kim S-J, Yu H, Kim MS, He J, et  al. Treatment of 
experimental human breast cancer and lung cancer brain metastases in mice 
by macitentan, a dual antagonist of endothelin receptors, combined with 
paclitaxel. Neuro Oncol (2016) 18:486–96. doi:10.1093/neuonc/now037 
99. Shimada IS, Borders A, Aronshtam A, Spees JL. Proliferating reactive astro-
cytes are regulated by Notch-1 in the peri-infarct area after stroke. Stroke 
(2011) 42:3231–7. doi:10.1161/STROKEAHA.111.623280 
100. Gril B, Palmieri D, Qian Y, Anwar T, Liewehr DJ, Steinberg SM, et  al. 
Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the 
brain metastatic microenvironment of breast cancer cells. Am J Pathol (2013) 
182:2368–79. doi:10.1016/j.ajpath.2013.02.043 
101. Clozel M. Endothelin research and the discovery of macitentan for the 
treatment of pulmonary arterial hypertension. Am J Physiol Regul Integr 
Comp Physiol (2016) 311:R721–6. doi:10.1152/ajpregu.00475.2015 
102. Kim S-J, Lee HJ, Kim MS, Choi HJ, He J, Wu Q, et al. Macitentan, a dual 
endothelin receptor antagonist, in combination with temozolomide leads 
to glioblastoma regression and long-term survival in mice. Clin Cancer Res 
(2015) 21:4630–41. doi:10.1158/1078-0432.CCR-14-3195 
103. Salameh A, Dhein S. Pharmacology of gap junctions. New pharmacological 
targets for treatment of arrhythmia, seizure and cancer? Biochim Biophys 
Acta (2005) 1719:36–58. doi:10.1016/j.bbamem.2005.09.007 
104. Harks EG, de Roos AD, Peters PH, de Haan LH, Brouwer A, Ypey DL, et al. 
Fenamates: a novel class of reversible gap junction blockers. J Pharmacol 
Exp Ther (2001) 298:1033–41. 
105. Chan WN, Evans JM, Hadley MS, Herdon HJ, Jerman JC, Parsons AA, 
et al. Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)- 
3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimi-
graine agent. Bioorg Med Chem Lett (1999) 9:285–90. doi:10.1016/
S0960-894X(98)00728-8 
106. Herdon HJ, Jerman JC, Stean TO, Middlemiss DN, Chan WN, Vong AK, 
et  al. Characterization of the binding of [3H]-SB-204269, a radiolabelled 
form of the new anticonvulsant SB-204269, to a novel binding site in rat 
brain membranes. Br J Pharmacol (1997) 121:1687–91. doi:10.1038/sj.bjp. 
0701331 
107. Read SJ, Smith MI, Hunter AJ, Upton N, Parsons AA. SB-220453, a potential 
novel antimigraine agent, inhibits nitric oxide release following induction 
of cortical spreading depression in the anaesthetized cat. Cephalalgia (2000) 
20:92–9. doi:10.1046/j.1468-2982.2000.00022.x 
108. Jin M, Dai Y, Xu C, Wang Y, Wang S, Chen Z. Effects of meclofenamic acid 
on limbic epileptogenesis in mice kindling models. Neurosci Lett (2013) 
543:110–4. doi:10.1016/j.neulet.2013.03.029 
109. Gril B, Palmieri D, Qian Y, Smart D, Ileva L, Liewehr DJ, et al. Pazopanib 
reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer 
brain metastasis. Clin Cancer Res (2011) 17:142–53. doi:10.1158/1078- 
0432.CCR-10-1603 
110. Sanz-Pamplona R, Aragüés R, Driouch K, Martín B, Oliva B, Gil M, et al. 
Expression of endoplasmic reticulum stress proteins is a candidate marker 
of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumors. 
Am J Pathol (2011) 179:564–79. doi:10.1016/j.ajpath.2011.04.037 
111. Desplat-Jégo S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, 
et al. TWEAK is expressed by glial cells, induces astrocyte proliferation and 
increases EAE severity. J Neuroimmunol (2002) 133:116–23. doi:10.1016/
S0165-5728(02)00368-5 
112. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. 
Science (2013) 342:1432–3. doi:10.1126/science.342.6165.1432 
113. Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, et al. Breast-
cancer-secreted miR-122 reprograms glucose metabolism in premetastatic 
niche to promote metastasis. Nat Cell Biol (2015) 17:183–94. doi:10.1038/
ncb3094 
114. Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, 
et  al. Premetastatic soil and prevention of breast cancer brain metastasis. 
Neuro Oncol (2013) 15:891–903. doi:10.1093/neuonc/not031 
115. Verkhratsky A, Matteoli M, Parpura V, Mothet J-P, Zorec R. Astrocytes as 
secretory cells of the central nervous system: idiosyncrasies of vesicular 
secretion. EMBO J (2016) 35:239–57. doi:10.15252/embj.201592705 
Conflict of Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2017 Wasilewski, Priego, Fustero-Torre and Valiente. This is an open- 
access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these terms.
